Literature DB >> 32377993

Chemistry and anti-herpes simplex virus type 1 evaluation of 4-substituted-1H-1,2,3-triazole-nitroxyl-linked hybrids.

Anna C Cunha1, Vitor F Ferreira2, Maria G F Vaz3, Rafael A Allão Cassaro4, Jackson A L C Resende5,6, Carolina Q Sacramento7, Jéssica Costa7, Juliana L Abrantes7, Thiago Moreno L Souza7,8, Alessandro K Jordão9.   

Abstract

HSV disease is distributed worldwide. Anti-herpesvirus drugs are a problem in clinical settings, particularly in immunocompromised individuals undergoing herpes simplex virus type 1 infection. In this work, 4-substituted-1,2,3-1H-1,2,3-triazole linked nitroxyl radical derived from TEMPOL were synthesized, and their ability to inhibit the in vitro replication of HSV-1 was evaluated. The nitroxide derivatives were characterized by infrared spectroscopy and elemental analysis, and three of them had their crystal structures determined by single-crystal X-ray diffraction. Four hybrid molecules showed important anti-HSV-1 activity with IC50 values ranged from 0.80 to 1.32 µM. In particular, one of the nitroxide derivatives was more active than Acyclovir (IC50 = 0.99 µM). All compounds tested were more selective inhibitors than the reference antiviral drug. Among them, two compounds were 4.5 (IC50 0.80 µM; selectivity index CC50/IC50 3886) and 7.7 times (IC50 1.10 µM; selectivity index CC50/IC50 6698) more selective than acyclovir (IC50 0.99 µM; selectivity index CC50/IC50: 869). These nitroxide derivatives may be elected as leading compounds due to their antiherpetic activities and good selectivity.
© 2020. Springer Nature Switzerland AG.

Entities:  

Keywords:  1H-1,2,3-triazole derivatives; Anti-HSV-1 activity; Crystal structure; TEMPOL-based radicals

Mesh:

Year:  2020        PMID: 32377993     DOI: 10.1007/s11030-020-10094-2

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  29 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Isosteric ribavirin analogues: Synthesis and antiviral activities.

Authors:  Nikolay I Zhurilo; Mikhail V Chudinov; Andrey V Matveev; Olga S Smirnova; Irina D Konstantinova; Anatoly I Miroshnikov; Alexander N Prutkov; Lyubov E Grebenkina; Natalya V Pulkova; Vitaly I Shvets
Journal:  Bioorg Med Chem Lett       Date:  2017-11-15       Impact factor: 2.823

Review 3.  Non-nucleoside inhibitors of herpesviruses.

Authors:  Michael W Wathen
Journal:  Rev Med Virol       Date:  2002 May-Jun       Impact factor: 6.989

4.  Anti-HSV-1 activity and mechanism of action of some new synthesized substituted pyrimidine, thiopyrimidine and thiazolopyrimidine derivatives.

Authors:  Salwa F Mohamed; Eman M Flefel; Abd El-Galil E Amr; Dina N Abd El-Shafy
Journal:  Eur J Med Chem       Date:  2010-01-13       Impact factor: 6.514

Review 5.  Management of viral infections in immunocompromised cancer patients.

Authors:  Pierre Reusser
Journal:  Swiss Med Wkly       Date:  2002-07-13       Impact factor: 2.193

6.  Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation.

Authors:  Y Chen; C Scieux; V Garrait; G Socié; V Rocha; J M Molina; D Thouvenot; F Morfin; L Hocqueloux; L Garderet; H Espérou; F Sélimi; A Devergie; G Leleu; M Aymard; F Morinet; E Gluckman; P Ribaud
Journal:  Clin Infect Dis       Date:  2000-10-10       Impact factor: 9.079

7.  Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman.

Authors:  Todd Czartoski; Charlie Liu; David M Koelle; Stephen Schmechel; Andrea Kalus; Anna Wald
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 8.  Medicinal attributes of 1,2,3-triazoles: Current developments.

Authors:  Divya Dheer; Virender Singh; Ravi Shankar
Journal:  Bioorg Chem       Date:  2017-01-18       Impact factor: 5.275

Review 9.  Antiviral Therapies for Herpesviruses: Current Agents and New Directions.

Authors:  Claudette L Poole; Scott H James
Journal:  Clin Ther       Date:  2018-08-10       Impact factor: 3.393

Review 10.  The molecular basis of herpes simplex virus latency.

Authors:  Michael P Nicoll; João T Proença; Stacey Efstathiou
Journal:  FEMS Microbiol Rev       Date:  2012-01-10       Impact factor: 16.408

View more
  2 in total

1.  The Role of Pyrazolopyridine Derivatives on Different Steps of Herpes Simplex Virus Type-1 In Vitro Replicative Cycle.

Authors:  Milene D Miranda; Otávio Augusto Chaves; Alice S Rosa; Alexandre R Azevedo; Luiz Carlos da Silva Pinheiro; Vinicius C Soares; Suelen S G Dias; Juliana L Abrantes; Alice Maria R Bernardino; Izabel C P Paixão; Thiago Moreno L Souza; Carlos Frederico L Fontes
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

Review 2.  Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.

Authors:  Lauren A Sadowski; Rista Upadhyay; Zachary W Greeley; Barry J Margulies
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.